These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 7973210)

  • 1. The clinical importance of early stopping of randomized trials in cancer treatments.
    Souhami RL
    Stat Med; 1994 Jul 15-30; 13(13-14):1293-5. PubMed ID: 7973210
    [No Abstract]   [Full Text] [Related]  

  • 2. Meta-analysis of randomized control trials applied to cancer therapy.
    Chalmers TC; Lau J
    Important Adv Oncol; 1992; ():235-41. PubMed ID: 1582675
    [No Abstract]   [Full Text] [Related]  

  • 3. [Regional adjuvant therapy in colorectal liver metastases: requirements for clinical therapy studies from the statistical viewpoint].
    Müller HH; Schäfer H
    Zentralbl Chir; 1995; 120(10):755-9. PubMed ID: 7502588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Data Monitoring Committees and early stopping guidelines: the Southwest Oncology Group experience.
    Crowley J; Green S; Liu PY; Wolf M
    Stat Med; 1994 Jul 15-30; 13(13-14):1391-9. PubMed ID: 7973218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Some practical aspects of the interim monitoring of clinical trials.
    Simon R
    Stat Med; 1994 Jul 15-30; 13(13-14):1401-9. PubMed ID: 7973219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Statistical considerations in the design, conduct and analyses of antiemetic clinical trials. An emerging consensus.
    Morrow GR; Ballatori E; Groshen S; Olver I
    Support Care Cancer; 1998 May; 6(3):261-5. PubMed ID: 9629880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surrogate and auxiliary endpoints in clinical trials, with potential applications in cancer and AIDS research.
    Fleming TR; Prentice RL; Pepe MS; Glidden D
    Stat Med; 1994 May; 13(9):955-68. PubMed ID: 8047747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SOP 09: Statistical design and analysis.
    Onkologie; 2003 Oct; 26 Suppl 6():43-7. PubMed ID: 23570186
    [No Abstract]   [Full Text] [Related]  

  • 9. The case against independent monitoring committees.
    Harrington D; Crowley J; George SL; Pajak T; Redmond C; Wieand S
    Stat Med; 1994 Jul 15-30; 13(13-14):1411-4. PubMed ID: 7973220
    [No Abstract]   [Full Text] [Related]  

  • 10. Interim analyses and stopping rules in cancer clinical trials.
    Whitehead J
    Br J Cancer; 1993 Dec; 68(6):1179-85. PubMed ID: 8260370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing treatment efficacy in the subset of responders in a randomized clinical trial.
    Korn EL; Othus M; Chen T; Freidlin B
    Ann Oncol; 2017 Jul; 28(7):1640-1647. PubMed ID: 28444115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant chemotherapy in endometrial cancer.
    Hogberg T
    Int J Gynecol Cancer; 2010 Oct; 20(11 Suppl 2):S57-9. PubMed ID: 20975363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How safe is adjuvant chemotherapy and radiotherapy for rectal cancer?
    Chao MW; Tjandra JJ; Gibbs P; McLaughlin S
    Asian J Surg; 2004 Apr; 27(2):147-61. PubMed ID: 15140670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. "Clinical benefit" following treatment with antineoplastic drugs: what does it mean and how should we measure it?
    Markman M
    Curr Oncol Rep; 1999 Sep; 1(1):1-2. PubMed ID: 11122791
    [No Abstract]   [Full Text] [Related]  

  • 15. [ASCO 2006. Exemestane: a new drug for the adjuvant therapy of breast cancer].
    Perrone F
    Tumori; 2006; 92(4):suppl 1-9. PubMed ID: 17036536
    [No Abstract]   [Full Text] [Related]  

  • 16. Early stopping of prevention trials when multiple outcomes are of interest: a discussion.
    Green SB; Freedman LS
    Stat Med; 1994 Jul 15-30; 13(13-14):1479-84. PubMed ID: 7973227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy of DC-CIK cells enhances the efficacy of chemotherapy for solid cancer: a meta-analysis of randomized controlled trials in Chinese patients.
    Lan XP; Chen YG; Wang Z; Yuan CW; Wang GG; Lu GL; Mao SW; Jin XB; Xia QH
    J Zhejiang Univ Sci B; 2015 Sep; 16(9):743-56. PubMed ID: 26365116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drop-out rates of cancer patients participating in longitudinal RCTs.
    Mathibe LJ
    Contemp Clin Trials; 2007 Jul; 28(4):340-2. PubMed ID: 17449332
    [No Abstract]   [Full Text] [Related]  

  • 19. Stopping trials early for benefit: too good to be true.
    Lancet; 2008 Apr; 371(9621):1310. PubMed ID: 18424306
    [No Abstract]   [Full Text] [Related]  

  • 20. [Adjuvant chemotherapy in the conception of multimodal cancer treatment (author's transl)].
    Tanneberger S
    Arch Geschwulstforsch; 1980; 50(2):160-4. PubMed ID: 7002090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.